Travere Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic from Q2 2013 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Travere Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q2 2013 to Q3 2024.
  • Travere Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 77.8M shares, a 1.93% increase year-over-year.
  • Travere Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 74.3M shares, a 16.5% increase from 2022.
  • Travere Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 63.8M shares, a 6.56% increase from 2021.
  • Travere Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 59.8M shares, a 25.9% increase from 2020.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 77.8M +1.47M +1.93% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 77.5M +1.5M +1.97% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 77.1M +8.96M +13.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 74.3M +10.5M +16.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 76.3M +12.3M +19.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 76M +12.4M +19.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 68.2M +5.04M +7.99% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 63.8M +3.93M +6.56% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 64M +3.23M +5.31% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 63.6M +3.07M +5.06% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 63.1M +6.86M +12.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 59.8M +12.3M +25.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 60.8M +9.87M +19.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 60.6M +15.8M +35.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 56.3M +13.1M +30.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 47.5M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 50.9M Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 44.8M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 43.1M +1.71M +4.14% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 41.4M +1.75M +4.42% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 39.7M +1.61M +4.24% Jan 1, 2018 Mar 31, 2018 10-Q/A 2018-07-06
Q4 2017 38.8M +1.77M +4.79% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 38.7M +1.67M +4.53% Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-07
Q2 2017 39M +2.36M +6.43% Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-09
Q1 2017 38M +1.53M +4.18% Jan 1, 2017 Mar 31, 2017 10-Q/A 2018-07-06
Q4 2016 37M +3.44M +10.2% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-26
Q3 2016 37M +1.24M +3.47% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 36.7M +1.73M +4.94% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 36.5M +9.36M +34.5% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q4 2015 33.6M +8.5M +33.9% Oct 1, 2015 Dec 31, 2015 10-K/A 2018-07-06
Q3 2015 35.7M +9.06M +34% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 35M +9.32M +36.4% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-05
Q1 2015 27.2M +3.82M +16.4% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 25.1M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-01
Q3 2014 26.7M +11.3M +73.7% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 25.6M +13.4M +109% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 23.3M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q3 2013 15.4M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 12.3M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.